Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMGN853 (Mirvetuximab Soravtansine) in Chinese Patients with Platinum-Resistant Ovarian Cancer
NCT05622890Phase 3Unknown
- Sponsor
- Huadong Medicine
- Start
- Aug 2022
- Primary completion
- Apr 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of mirvetuximab soravtansine in Epithelial Ovarian Cancer (EOC), primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC), sponsored by Huadong Medicine. Primary endpoint: Objective Response Rate up to 2 years. Status: unknown.
02
Drugs
mirvetuximab soravtansine
03
Conditions
Epithelial Ovarian Cancer (EOC)primary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT05622890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05622890.